Literature DB >> 1539148

Role of alginate in infection with mucoid Pseudomonas aeruginosa in cystic fibrosis.

S S Pedersen1, N Høiby, F Espersen, C Koch.   

Abstract

BACKGROUND: Chronic bronchopulmonary infection with mucoid, alginate producing Pseudomonas aeruginosa occurs characteristically in patients with cystic fibrosis. Alginate may be a virulence factor for P aeruginosa infection in such patients.
METHODS: Forced vital capacity (FVC), nutritional state and the antibody response to P aeruginosa were determined at regular intervals from three years before chronic P aeruginosa infection to 10 years afterwards in 73 patients with cystic fibrosis. All patients were treated intensively with antipseudomonal chemotherapy during the study period.
RESULTS: FVC was reduced in all patients who subsequently developed P aeruginosa infection before they acquired the infection, indicating significant pre-existing lung damage when compared with patients who remained free of P aeruginosa. Lung function and nutritional state remained unchanged after 10 years of infection, except in the patients who died of P aeruginosa lung infection. The FVC and height and weight of patients infected with nonmucoid strains of P aeruginosa were similar to those of uninfected patients. Patients infected with mucoid strains had poorer lung function and nutritional state for the first five years after infection compared with patients with nonmucoid strains. Such infection was also associated with greater IgG and IgA antibody responses to P aeruginosa standard antigen compared with nonmucoid infection. Concentrations of antibody to alginate were similar in patients with non-mucoid and mucoid infection. Noticeably increased concentrations of IgA antibodies to P aeruginosa standard antigen were observed early after the onset of infection in patients who subsequently died.
CONCLUSION: Alginate producing P aeruginosa infection is associated with a hyperimmune response and poor clinical condition, suggesting that alginate production is a virulence factor in such infections in patients with cystic fibrosis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1539148      PMCID: PMC463537          DOI: 10.1136/thx.47.1.6

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  34 in total

1.  Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa.

Authors:  E Kerem; M Corey; R Gold; H Levison
Journal:  J Pediatr       Date:  1990-05       Impact factor: 4.406

Review 2.  The role of immune complexes in the pathogenesis of bacterial infections.

Authors:  N Høiby; G Döring; P O Schiøtz
Journal:  Annu Rev Microbiol       Date:  1986       Impact factor: 15.500

3.  Bacterial precipitins in serum of patients with cystic fibrosis.

Authors:  M W Burns; J R May
Journal:  Lancet       Date:  1968-02-10       Impact factor: 79.321

4.  [Heights and weights of Danish children].

Authors:  E Andersen; B Hutchings; J Jansen; M Nyholm
Journal:  Ugeskr Laeger       Date:  1982-06-14

5.  Alginate biosynthetic enzymes in mucoid and nonmucoid Pseudomonas aeruginosa: overproduction of phosphomannose isomerase, phosphomannomutase, and GDP-mannose pyrophosphorylase by overexpression of the phosphomannose isomerase (pmi) gene.

Authors:  I Sá-Correia; A Darzins; S K Wang; A Berry; A M Chakrabarty
Journal:  J Bacteriol       Date:  1987-07       Impact factor: 3.490

6.  Serum immunoglobulin levels in cystic fibrosis.

Authors:  R H Schwartz
Journal:  Am J Dis Child       Date:  1966-04

7.  Multiple of isolates of Pseudomonas aeruginosa with differing antimicrobial susceptibility patterns from patients with cystic fibrosis.

Authors:  M J Thomassen; C A Demko; B Boxerbaum; R C Stern; P J Kuchenbrod
Journal:  J Infect Dis       Date:  1979-12       Impact factor: 5.226

8.  Alginate production by clinical nonmucoid Pseudomonas aeruginosa strains.

Authors:  E D Anastassiou; A C Mintzas; C Kounavis; G Dimitracopoulos
Journal:  J Clin Microbiol       Date:  1987-04       Impact factor: 5.948

9.  Management of Pseudomonas aeruginosa lung infection in Danish cystic fibrosis patients.

Authors:  S S Pedersen; T Jensen; N Høiby; C Koch; E W Flensborg
Journal:  Acta Paediatr Scand       Date:  1987-11

10.  Purification, characterization, and immunological cross-reactivity of alginates produced by mucoid Pseudomonas aeruginosa from patients with cystic fibrosis.

Authors:  S S Pedersen; F Espersen; N Høiby; G H Shand
Journal:  J Clin Microbiol       Date:  1989-04       Impact factor: 5.948

View more
  67 in total

1.  Specific and rapid detection by fluorescent in situ hybridization of bacteria in clinical samples obtained from cystic fibrosis patients.

Authors:  M Hogardt; K Trebesius; A M Geiger; M Hornef; J Rosenecker; J Heesemann
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

2.  In vitro alginate polymerization and the functional role of Alg8 in alginate production by Pseudomonas aeruginosa.

Authors:  Uwe Remminghorst; Bernd H A Rehm
Journal:  Appl Environ Microbiol       Date:  2006-01       Impact factor: 4.792

3.  Alginate lyase (AlgL) activity is required for alginate biosynthesis in Pseudomonas aeruginosa.

Authors:  Mark T Albrecht; Neal L Schiller
Journal:  J Bacteriol       Date:  2005-06       Impact factor: 3.490

4.  Epimerase active domain of Pseudomonas aeruginosa AlgG, a protein that contains a right-handed beta-helix.

Authors:  Stephanie A Douthit; Mensur Dlakic; Dennis E Ohman; Michael J Franklin
Journal:  J Bacteriol       Date:  2005-07       Impact factor: 3.490

Review 5.  Quorum-sensing blockade as a strategy for enhancing host defences against bacterial pathogens.

Authors:  Thomas Bjarnsholt; Michael Givskov
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2007-07-29       Impact factor: 6.237

6.  Impact of alginate overproduction on attachment and biofilm architecture of a supermucoid Pseudomonas aeruginosa strain.

Authors:  Iain D Hay; Kali Gatland; Andrea Campisano; J Zoe Jordens; Bernd H A Rehm
Journal:  Appl Environ Microbiol       Date:  2009-07-31       Impact factor: 4.792

Review 7.  Lung infections. 3. Pseudomonas aeruginosa and other related species.

Authors:  R Wilson; R B Dowling
Journal:  Thorax       Date:  1998-03       Impact factor: 9.139

Review 8.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

9.  Polydopamine-Mediated Immobilization of Alginate Lyase to Prevent P. aeruginosa Adhesion.

Authors:  Diana Alves; Tadas Sileika; Phillip B Messersmith; Maria Olívia Pereira
Journal:  Macromol Biosci       Date:  2016-05-19       Impact factor: 4.979

10.  Evolutionary remodeling of global regulatory networks during long-term bacterial adaptation to human hosts.

Authors:  Søren Damkiær; Lei Yang; Søren Molin; Lars Jelsbak
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-22       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.